Newer Therapeutics to Selectively Kill Clostridioides difficile and Restore the Microbiome
BACKGROUND: . METHODS: Data sources: PubMed and SCOPUS databases were searched from 1 January 2012 to 15 November 2025. Original articles reporting data on ibezapolstat and live-JSLM were included. RESULTS: antibiotic regimen. CONCLUSIONS: infection: starting with highly specific antibiotics, i.e., ibezapolstat, followed by microbiome-based therapies such as live-JSLM.
Authors
- Guido Granata (ORCID: https://orcid.org/0000-0001-5796-0545)
- Nicola Petrosillo (ORCID: https://orcid.org/0000-0002-2585-7567)
Institutions
- Center for Prevention and Treatment of Infections (US)
- Campus Bio Medico University Hospital (IT)
Publication Details
- Journal
- Infectious Disease Reports
- Published
- 2026-04-11
- DOI
- https://doi.org/10.3390/idr18020034
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.00